FDA Toughens Up About Prescription Drugs Labeling

The FDA is pressing forward in regards to prescription labeling. A most popular know case with the makers of Antidepressants due to birth defects. This has caught the attention of the FDA and many researchers, doctors and patients. With little information at hand, no one knows what percentage of the population has been affected from Zoloft birth defects. This is one of many reasons the FDA has stepped in yet again in order to regulate the pharmaceutical market. Proper labeling is required by the FDA approved prescriptions. Did I say FDA approved? Could the FDA have done more in order to prevent so many heart breaks from birth defects? The FDA toughens up about prescription drugs labeling, only too late for a lot of families affected from SSRI antidepressants, like Zoloft, taken during pregnancies. Who regulates the decisions the FDA makes on behalf of the antidepressant makers and the consumers. Who’s interest do they really have at hand? With so many questions still unanswered, who is to blame? Doctors know only what the makers of the drugs tell them. Like everyone else, they also base a decision according to the warning labels. For this very reason many question the makers of antidepressant drugs. It should be interesting to see just how much information they will release to the public.